| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Meakins-Christie Laboratories and Respiratory Division, McGill University, Montreal, Quebec, Canada
2 Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada; National Research Council of Canada, Biotechnology Research Institute, Montreal, Quebec, Canada
3 Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
4 Meakins-Christie Laboratories and Respiratory Division, McGill University, Montreal, Quebec, Canada; Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada
* To whom correspondence should be addressed. E-mail: basil.petrof{at}mcgill.ca.
Duchenne muscular dystrophy is caused by defects in the dystrophin gene, and the mdx mouse is the most frequently employed genetic model of this disease. It is well known that different muscle groups do not respond in the same way to dystrophin deficiency. In particular, the mdx mouse diaphragm exhibits severe morphological and functional changes not found in other mdx muscles. Use of early generation adenoviral vectors to deliver genes to the diaphragm in immunocompetent mdx mice has been associated with substantial functional toxicity and a rapid loss of transgene expression. Here we determined the response to dystrophin gene replacement in the mdx diaphragm using a "gutted" adenoviral vector, which contains the coding sequence of two full-length dystrophin genes and is deleted of most viral DNA sequences. At 1 week post-delivery of the vector, 23.6 ± 4 % of total fibers in the injected diaphragm bundle expressed dystrophin at the sarcolemma, which remained stable over the study duration of 30 days without the need for continuous immunosuppression. Treated diaphragms showed a significantly improved resistance to the abnormal force deficits induced by high-stress muscle contractions, the latter being a functional hallmark of dystrophin-deficient muscle. This functional amelioration was achieved despite the presence of mildly increased inflammation (CD4+ and CD8+ lymphocytes) within the vector-treated diaphragms. To our knowledge, this is the first demonstration that a viral vector can achieve reversal of functional abnorrmalities in the dystrophic diaphragm via therapeutic dystrophin gene transfer, without the need for sustained immunosuppressive therapy.
This article has been cited by other articles:
|
|
 |
|
  J. Davis, M. V. Westfall, D. Townsend, M. Blankinship, T. J. Herron, G. Guerrero-Serna, W. Wang, E. Devaney, and J. M. Metzger Designing Heart Performance by Gene Transfer Physiol Rev, October 1, 2008; 88(4): 1567 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Adriaansen, M. J. B. M. Vervoordeldonk, and P. P. Tak Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes Rheumatology, June 1, 2006; 45(6): 656 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R. A. Aoki, H. Liu, G. P. Downey, J. Mitchell, and R. L. Horner Cyclic Nucleotides Modulate Genioglossus and Hypoglossal Responses to Excitatory Inputs in Rats Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 555 - 565. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Demoule, M. Divangahi, G. Danialou, D. Gvozdic, G. Larkin, W. Bao, and B. J. Petrof Expression and Regulation of CC Class Chemokines in the Dystrophic (mdx) Diaphragm Am. J. Respir. Cell Mol. Biol., August 1, 2005; 33(2): 178 - 185. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
